Cluster Health & Mission Cancer Brokerage Event

28 Sept 2026 | Brussels, Belgium

Register
Register
Register

Project cooperationUpdated on 6 August 2026

(CANCER-03) GMP manufacturing and first-in-human trial delivery for rare-cancer therapeutics

EU Grants and Funding Coordinator at Elpen Pharmaceutical Co. Inc.

Athens, Greece

About

ELPEN Pharmaceutical and its affiliated Athens LifeTech Park (Greece) offer an integrated preclinical-to-first-in-human capability for HORIZON-MISS-2027-02-CANCER-03.

ELPEN can manufacture and release the investigational oncology drug to GMP standard, supported by an emerging dedicated high-potent/cytotoxic manufacturing facility, provide formulation and drug-product development, author the manufacturing-quality (CMC) section of the regulatory/CTA submission, and act as the exploitation/commercialisation partner toward validation and market.

Via Athens LifeTech Park, the group finalises preclinical validation (in vivo and ex vivo models, rodent and swine, plus DMPK and bioanalysis), and delivers Phase 1, including first-in-human, multi-centre trials through its early-phase CRO with EU site management and registry-powered recruitment; LC-MS/MS and ligand-binding bioanalysis support safety/efficacy endpoints. Drug repurposing, explicitly in scope, fits ELPEN's develop-and-make model.

ALTP's incubator can bring qualifying start-ups/asset-owners.

Topic

  • Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes

Type

  • Partner seeks Consortium/Coordinator

Organisation

Elpen Pharmaceutical Co. Inc.

Company (Industry)

Athens, Greece

Similar opportunities